ConductScience.org, home

Paper39792181

Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.

Cheng CY and 7 others. Cancer Chemother Pharmacol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study. Papers, record 39792181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39792181

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-27
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cheng CYChing-Yuan
2Chuang WCWen-Chen
3Lin CPChing-Pin
4Li CHChe-Hsing
5Chang HYHui-Yi
6Wu WJWen-Jun
7Wu MFMing-Fang
8Ko JLJiunn-Liang

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PemetrexedMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
EndoglinMajor topic
Biomarkers, TumorMajor topic
Cell MovementMajor topic
Humans
Cell Line, Tumor
Drug Resistance, Neoplasm
Antineoplastic Agents
A549 Cells
Cell Proliferation
Cell Cycle

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CSH-2021-C-031Chung Shan Medical University HospitalPubMed
MOST 111-2314-B-040-131Taiwan National Science and Technology CouncilPubMed
MOST 111-2320-B-040-018-MY3Taiwan National Science and Technology CouncilPubMed
097-CCH-CSMU-04Changhua Christian HospitalPubMed

Source PubMed

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138754467Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw2024https://conductscience.org/library/papers/38754467PubMed
217308042Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.Mol Cancer Ther2007https://conductscience.org/library/papers/17308042PubMed
329682186Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.Oncotarget2018https://conductscience.org/library/papers/29682186PubMed
420559153Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.J Thorac Oncol2010https://conductscience.org/library/papers/20559153PubMed
527270426The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.Oncogene2017https://conductscience.org/library/papers/27270426PubMed
611164421Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques.Atherosclerosis2000https://conductscience.org/library/papers/11164421PubMed
715806144Characterization of murine S-endoglin isoform and its effects on tumor development.Oncogene2005https://conductscience.org/library/papers/15806144PubMed
818303046L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts.J Cell Sci2008https://conductscience.org/library/papers/18303046PubMed
921737653Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.Anticancer Res2011https://conductscience.org/library/papers/21737653PubMed
1031897911Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis.Angiogenesis2020https://conductscience.org/library/papers/31897911PubMed
1134587660Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.Mol Carcinog2022https://conductscience.org/library/papers/34587660PubMed
1235664553Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).Neurooncol Adv2022https://conductscience.org/library/papers/35664553PubMed
1320981476Endoglin suppresses human prostate cancer metastasis.Clin Exp Metastasis2011https://conductscience.org/library/papers/20981476PubMed
1421042283Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome.Oncogene2011https://conductscience.org/library/papers/21042283PubMed
1519736306Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.Carcinogenesis2010https://conductscience.org/library/papers/19736306PubMed
1617496924Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.Oncogene2007https://conductscience.org/library/papers/17496924PubMed
1726325105Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer.Br J Cancer2015https://conductscience.org/library/papers/26325105PubMed
1835221721Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer.Cancer Manag Res2021https://conductscience.org/library/papers/35221721PubMed
1921575631Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells.Eur J Pharmacol2011https://conductscience.org/library/papers/21575631PubMed
2027156098Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.DNA Repair (Amst)2016https://conductscience.org/library/papers/27156098PubMed

See all 28 referencesDownload CSV of references

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCNA2890PubTator's text mininghttps://conductscience.org/library/genes/890NCBI Gene
CDK21017PubTator's text mininghttps://conductscience.org/library/genes/1017NCBI Gene
CDKN1A1026PubTator's text mininghttps://conductscience.org/library/genes/1026NCBI Gene
ENG2022PubTator's text mininghttps://conductscience.org/library/genes/2022NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39792181

GET https://conductscience.org/api/papers/v1/39792181/references?page=2